Select Bibliography

Filter by any of these (after searching):

Gastrointestinal Cancers Symposium

AUTHOR ABSTRACT DEADLINES

A meeting abstract must be submitted by the first or corresponding author to the Alliance Publications Coordinator (publications@AllianceNCTN.org) at least two weeks prior to the meeting abstract submission deadline. For detailed information about Alliance Publications guidelines, please refer to the policies, along with the author abstract deadlines.

There are 11 items

NCCTG phase II trial (N044J) of AZD2171 for patients with hepatocellular carcinoma (HCC)--interim review of toxicity

Alberts, S. R. , Morlan, B. W. , Kim, G. P. , Pitot, H. C. ... - ASCO GI - Gastrointestinal Cancers Symposium - 2007

Abstract - Primary - Preliminary - GI - NCCTG-N044J

Efficacy of adjuvant imatinib mesylate following complete resection of localized, primary gastrointestinal stromal tumor (GIST) at high risk of recurrence: The U.S. Intergroup phase II trial ACOSOG Z9000

Dematteo, R. P. , Owzar, K. , Antonescu, C. R. , Maki, R. ... - ASCO GI - Gastrointestinal Cancers Symposium - 2008

Abstract - Primary - Primary - GI - ACOSOG-Z9000

Baseline quality of life (QOL) is a strong and performance status (PS)-independent prognostic factor for overall survival (OS) in patients with metastatic colorectal cancer (mCRC)

Grothey, A. , Sargent, D. J. , Szydlo, W. , Zhao, X. , Campbell, M. ... - ASCO GI - Gastrointestinal Cancers Symposium - 2008

Abstract - Secondary - Primary - GI - NCCTG-N9741

Phase II study of oxaliplatin, 5-FU and RT followed by gemcitabine in patients with unresectable pancreatic cancer.

Haddock, M. , Kim, G. , Foster, N. , Bollinger, J. , Stella, P. ... - ASCO GI - Gastrointestinal Cancers Symposium - 2007

Abstract - Primary - Primary - GI - NCCTG-N0349

Phase II study of oxaliplatin (OX), 5-fluorouracil (5-FU) and radiation therapy (RT) followed by gemcitabine (GEM) in patients with unresectable pancreatic cancer

Kim, G. P. , Haddock, M. G. , Foster, N. , Bollinger, J. , Stella, P. ... - ASCO GI - Gastrointestinal Cancers Symposium - 2008

Abstract - Primary - Long-Term-Followup - GI - NCCTG-N0349

Time-dependent patterns of treatment effect and failure as an explanation for the predictive role of deficient mismatch repair (dMMR) in colon cancer.

Kim, G. , Marsoni, S. , Monges, G. , Allegra, C. , Thibodeau, S. N. ... - ASCO GI - Gastrointestinal Cancers Symposium - 2010

Abstract - Secondary - Primary - GI - NCCTG-N994C

Phase II trial of oxaliplatin, irinotecan, 5-fluorouracil, and leucovorin for metastatic colorectal cancer

Mcwilliams, R. , Goetz, M. , Morlan, B. , Salim, M. , Rowland, K., Jr ... - ASCO GI - Gastrointestinal Cancers Symposium - 2007

Abstract - Primary - Primary - GI - NCCTG-N0341

Combined-modality therapy of poor prognosis anal canal carcinoma: a phase II study of the Cancer and Leukemia Group B (CALGB)

Meropol, N. J. , Niedzwiecki, D. , Shank, B. , Colacchio, T. ... - ASCO GI - Gastrointestinal Cancers Symposium - 2005

Abstract - Primary - Primary - GI - CALGB-9281

Use of the ratio of metastatic to examined lymph nodes to predict local recurrence in rectal cancer: Analysis of data from intergroup trial 0114.

Meyers, M. O. , Hollis, D. R. , Mayer, R. J. , Goldberg, R. M. ... - ASCO GI - Gastrointestinal Cancers Symposium - 2009

Abstract - Secondary - Primary - GI - INT-0114

Overall and 12 week tumor response versus actual tumor measurements as predictors of overall survival (OS) in advanced colorectal cancer (ACRC): Findings from NCCTG N9741.

Sargent, D. J. , Campbell, M. E. , Grothey, A. ... - ASCO GI - Gastrointestinal Cancers Symposium - 2008

Abstract - Secondary - Primary - GI - NCCTG-N9741

Evaluation of recurrence rate,time-to-recurrence, and hepatic metastases in patients with colon cancers with defective DNA mismatch repair.

Sinicrope, F. , Foster, N. R. , Sargent, D. J. , Thibodeau, S. N. ... - ASCO GI - Gastrointestinal Cancers Symposium - 2010

Abstract - Secondary - Primary - GI - NCCTG-N994C